To evaluate the combined influence of SMS1 plus SMS2 gene expression in glioma patients, 4 groups were evaluated (SMS1-high plus SMS2-low, SMS1-low plus SMS2-low, SMS1-high plus SMS2-high and SMS1-low plus SMS2-high), and significant differences were observed (Figure 3A). The gene discussed is SGMS2; the disease is central nervous system cancer.